Furthermore, PXR knockdown using shRNA constructs enhanced the chemosensitivity of prostate cancer cells to chemotherapeutic drugs, suggesting a contributing role of PXR to chemoresistance in prostate cancer[32]. This evidence concerns the gene NR1I2 and Familial prostate cancer.